Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Congressional Report Finds FDA Ignored Agency Protocols in Approving Biogen’s Aduhelm Alzheimer’s Drug Biogen and FDA held numerous improperly documented meetings designed to drag Aduhelm through the approval process despite a lack of evidence showing the drug worked, the report found December 30, 2022 Irvin Jackson Add Your Comments Concerns have been raised about whether federal drug regulators failed to follow their own standard protocols when approving the controversial Alzheimer’s disease drug Aduhelm, after a new Congressional report suggests that the FDA had an unusually close relationship with Biogen, the manufacturer. Aduhelm became the first novel therapy approved for the treatment of Alzheimer’s since 2003, after it was granted approval through the FDA’s Accelerated Approval Program in June 2022. The drug is designed to reduce the presence of amyloid beta plaques in the brain, which are believed to be linked to the progression of the disease. However, the decision to approve the medication immediately raised questions, since it followed the unanimous recommendation against approval by a panel of independent advisors to the FDA, due to questions about Aduhelm’s effectiveness treating Alzheimer’s. Following an 18 month investigation that looked into why the drug was approved, a joint report was released this week by the U.S. House of Representative’s Committee on Oversight and Reform, and Committee on Energy and Commerce, titled “The High Price of Aduhlem’s Approval” (PDF), highlighting the overly cozy releationship between the FDA and Biogen. Do You Know about… SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Do You Know About… SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit. Learn More SEE IF YOU QUALIFY FOR COMPENSATION The agency’s approval led to several members of the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee resigning in protest, and several congressional committees are looking into the decision. The agency has since faced a number of serious questions, such as why the FDA approved the drug when its own experts said it should not, and whether there was an improper working relationship between the agency and the drug’s manufacturer, Biogen. Lawmakers Question FDA, Biogen Relationship and Aduhelm Approval House staffers reviewed more than 500,000 pages on documents and held multiple briefings with the FDA. “The Committees’ review of these materials reveals that FDA’s review and approval of Aduhelm consisted of atypical procedures and deviated from the agency’s own guidance,” the report determines. “These materials also reveal that Biogen had aggressive launch plans for Aduhelm – including in its label and pricing – despite concerns about efficacy, safety, and affordability.” The House report notes that the FDA’s accelerated approval of Aduhelm occurred despite the fact that Biogen had cancelled clinical trials for the Alzheimer’s drug in March 2019. Aduhelm is supposed to reduce amyloid beta plaque in the brain, but an independent report at the time found it was unlikely to be a benefit to Alzheimer’s patients and determined no further clinical trials should be conducted. However, just three months after the clinical trials were cancelled, FDA staff members and Biogen formed a “working group” which engaged in at least 115 meetings, calls and email discussions over the next year. At least 40 of those meetings were focused on dragging Aduhelm through the approval process despite evidence the drug just did not work. The House investigators found some of the meetings were not properly documented according to FDA protocols, raising suspicions. The report determined that the FDA’s interactions with Biogen were atypical, failing to follow the agency’s documentation protocol on many occasions, making it hard to determine what happened at those meetings. At least 40 working group meetings between FDA staff and Biogen, 66 phone calls and a substantial number of email exchanges were not properly documented, House staffers determined. House investigators also found that the FDA and Biogen inappropriately collaborated to create a joint briefing document for the FDA Advisory Committee. Even that was not enough to prevent the FDA’s advisors from resoundingly rejecting Aduhelm, which did not stop the FDA from approving it. “The Committees obtained evidence that FDA and Biogen staff worked closely for several months ahead of the November 6, 2020, PCNS Advisory Committee meeting to prepare the joint briefing document for the Committee’s review,” the investigators wrote. “Documents show that using a joint briefing document afforded Biogen advance insight into FDA’s responses and direct guidance from the agency in drafting the company’s own sections.” Despite the failed clinical trials, and despite the rejection by the FDA’s own panel of advisors, the agency granted Aduhelm accelerated approval anyway, and then when the drug came out, investigators found that Biogen planned to set an unusually high price of $56,000 per year for treatment. Then the company planned to spend $3.3 billion to market the drug, which is three times how much it cost to develop. “The findings in this report raise serious concerns about FDA’s lapses in protocol and Biogen’s disregard of efficacy and access in the approval process for Aduhelm,” the report concludes “The criticism surrounding Aduhelm’s approval pay have been avoided had FDA adhered to its own guidance and internal practices. FDA must take swift action to ensure that its process for reviewing future Alzheimer’s disease treatments do not lead to the same doubts about the integrity of FDA’s review.” Tags: Aduhelm, Alzheimer's Disease, Biogen, Congress More Lawsuit Stories Lawyers To Select 50 Suboxone Dental Lawsuits for Next Phase of MDL Bellwether Discovery May 22, 2025 Talc Safety To Be Subject of New Independent Scientific Expert Panel Led by FDA May 22, 2025 GeekVape Aegis Lawsuit Filed Over Severe Burns Caused by Vape Pen Explosion May 22, 2025 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermNameThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Lawyers To Select 50 Suboxone Dental Lawsuits for Next Phase of MDL Bellwether Discovery (Posted: today) As lawyers continue to review records on more than 500 Suboxone tooth decay lawsuits, the MDL judge has outlined the process for identifying a smaller group that will move into the next discovery phase. MORE ABOUT: SUBOXONE TOOTH DECAY LAWSUIT500 Suboxone Tooth Decay Cases Randomly Selected for Bellwether Record Collection Pool (04/24/2025)Status of Suboxone Tooth Loss Lawsuits To Be Reviewed at MDL Conference (04/16/2025)Prenatal Opioid Exposure May Result in Smaller Brains Among Newborns: Study (04/14/2025) Hair Relaxer Lawsuits MDL Judge Seeks Status Report on Discovery Proceedings (Posted: yesterday) A federal judge wants lawyers involved in hair relaxer lawsuits to provide an update this week on the status of discovery proceedings for a pool of cases being considered for bellwether trial dates. MORE ABOUT: HAIR RELAXER LAWSUITFormaldehyde Found in Range of Personal Care Products Used Primarily by Black and Latina Women (05/14/2025)Lawyers Selected 32 Hair Relaxer Lawsuits for Bellwether Discovery in MDL (05/13/2025)Hair Relaxer Settlement Master Appointed To Oversee Negotiations To Resolve Cancer Lawsuits (04/29/2025) Covidien Parietex Optimized Composite (PCOx) Hernia Mesh Lawsuits To Be Prepared for Trial (Posted: yesterday) Two Covidien Parietex Optimized Composite hernia mesh lawsuits have been chosen to be prepared to potentially serve as the third Covidien hernia mesh bellwether trial. MORE ABOUT: HERNIA MESH LAWSUITSecond Bellwether Trial in Covidien Hernia Mesh Lawsuit MDL Set for July 2026 (05/14/2025)Covidien Mesh Lawsuit Set For Trial in Feb. 2026, Over Defective Hernia Implant (04/10/2025)New Bard Hernia Mesh Lawsuits Continue To Be Filed Following Global Settlement (04/03/2025)
Lawyers To Select 50 Suboxone Dental Lawsuits for Next Phase of MDL Bellwether Discovery May 22, 2025
Lawyers To Select 50 Suboxone Dental Lawsuits for Next Phase of MDL Bellwether Discovery (Posted: today) As lawyers continue to review records on more than 500 Suboxone tooth decay lawsuits, the MDL judge has outlined the process for identifying a smaller group that will move into the next discovery phase. MORE ABOUT: SUBOXONE TOOTH DECAY LAWSUIT500 Suboxone Tooth Decay Cases Randomly Selected for Bellwether Record Collection Pool (04/24/2025)Status of Suboxone Tooth Loss Lawsuits To Be Reviewed at MDL Conference (04/16/2025)Prenatal Opioid Exposure May Result in Smaller Brains Among Newborns: Study (04/14/2025)
Hair Relaxer Lawsuits MDL Judge Seeks Status Report on Discovery Proceedings (Posted: yesterday) A federal judge wants lawyers involved in hair relaxer lawsuits to provide an update this week on the status of discovery proceedings for a pool of cases being considered for bellwether trial dates. MORE ABOUT: HAIR RELAXER LAWSUITFormaldehyde Found in Range of Personal Care Products Used Primarily by Black and Latina Women (05/14/2025)Lawyers Selected 32 Hair Relaxer Lawsuits for Bellwether Discovery in MDL (05/13/2025)Hair Relaxer Settlement Master Appointed To Oversee Negotiations To Resolve Cancer Lawsuits (04/29/2025)
Covidien Parietex Optimized Composite (PCOx) Hernia Mesh Lawsuits To Be Prepared for Trial (Posted: yesterday) Two Covidien Parietex Optimized Composite hernia mesh lawsuits have been chosen to be prepared to potentially serve as the third Covidien hernia mesh bellwether trial. MORE ABOUT: HERNIA MESH LAWSUITSecond Bellwether Trial in Covidien Hernia Mesh Lawsuit MDL Set for July 2026 (05/14/2025)Covidien Mesh Lawsuit Set For Trial in Feb. 2026, Over Defective Hernia Implant (04/10/2025)New Bard Hernia Mesh Lawsuits Continue To Be Filed Following Global Settlement (04/03/2025)